Axon Steven 4
4 · Apellis Pharmaceuticals, Inc. · Filed Nov 15, 2018
Insider Transaction Report
Form 4
Axon Steven
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2018-11-14$2.59/sh+11,500$29,785→ 50,110 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-11-14−11,500→ 348,389 totalExercise: $2.59Exp: 2027-05-17→ Common Stock (11,500 underlying)
Footnotes (2)
- [F1]This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.
- [F2]This option was granted on May 18, 2017 and will vest as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.